Reduced BCL2, BCLXL, and MCL1 protein in AML patient cells treated with ruxolitinib and venetoclax. (A) Western blot analysis of BCL2, BCLXL, and MCL1 proteins in AML patient cells after treatment with 300 nM ruxolitinib (RUX), 100 nM venetoclax (VEN), or a combination of both drugs (COMB) in 25% HS-5 CM. Protein lysates for patient cells (n = 5) were collected 48 hours after drug treatment and analyzed by immunoblotting, using antibodies to the antigens indicated. Results are shown for patients 5237, 5249, 5750, 4701010, and 5238. (B) Quantification of relative protein levels for BCL2, BCLXL, and MCL1 by analysis of chemiluminescence signals, using Odyssey v2.0 software corrected to the intensities obtained with the β-actin antibody.